


PHARMACEUTICAL 2022

Angion Biomedica Corp. Rank 332 of 475





PHARMACEUTICAL 2022

Angion Biomedica Corp. Rank 332 of 475

The relative strengths and weaknesses of Angion Biomedica Corp. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Angion Biomedica Corp. compared to the market average is the variable Revenues, increasing the Economic Capital Ratio by 96% points. The greatest weakness of Angion Biomedica Corp. is the variable Research and Development, reducing the Economic Capital Ratio by 112% points.

The company's Economic Capital Ratio, given in the ranking table, is -236%, being 41% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	91,247
Cost of Goods Sold	433
Intangible Assets	0
Liabilities, Current	11,296
Liabilities, Non-Current	3,475
Other Assets	4,815
Other Compr. Net Income	230
Other Expenses	0
Other Liabilities	235
Other Net Income	-15,266
Property and Equipment	451
Research and Development	48,698
Revenues	28,312
Selling, General and Administrative Expense	18,488

Output Variable	Value in 1000 USD
Assets	96,513
Liabilities	15,006
Expenses	67,619
Stockholders Equity	81,507
Net Income	-54,573
Comprehensive Net Income	-54,458
Economic Capital Ratio	-236%